PCN106 Cost-Minimization and Budget Impact Analysis of Venetoclax plus Obinutuzumab Versus Ibrutinib in Patients with Untreated Chronic Lymphocytic Leukemia in the Brazilian Private Healthcare System
Abstract
Authors
F.M. Vieira G.N. Ribeiro Filho C Brito A. Travassos